Abstract Number: 2873 • 2018 ACR/ARHP Annual Meeting
Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
Background/Purpose: The incidence of fibromyalgia is highest in the first 12 months after RA diagnosis,1 indicating that this period may represent a critical window during…Abstract Number: 2874 • 2018 ACR/ARHP Annual Meeting
Comparison of Missing Data Reporting and Handling in Randomized Controlled Trials of Rheumatoid Arthritis Drug Therapy: A Snapshot Ten Years Apart
Background/Purpose: Intention-to-treat (ITT) principle is recommended to analyze randomized controlled trials (RCTs). It entails analyzing all subjects per the assigned group at randomization to avoid…Abstract Number: 2875 • 2018 ACR/ARHP Annual Meeting
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Background/Purpose: Among patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the addition of a biologic DMARD…Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…Abstract Number: 2879 • 2018 ACR/ARHP Annual Meeting
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
Background/Purpose: TNF-α inhibitors are among the most widely used biological-DMARDs in rheumatoid arthritis (RA). Means to predict response would allow for a more effective, targeted…Abstract Number: 2880 • 2018 ACR/ARHP Annual Meeting
Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been demonstrated to be involved in B-cell lymphoproliferation and lymphoma mainly by tissue studies on salivary glands (SG) biopsies…Abstract Number: 2881 • 2018 ACR/ARHP Annual Meeting
How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)
Background/Purpose: To evaluate the influence of the main immunological markers on the disease phenotype at diagnosis in a large international cohort of patients with primary…Abstract Number: 2882 • 2018 ACR/ARHP Annual Meeting
Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Background/Purpose: Classical connective tissue diseases, such as SLE and RA have well documented progression of disease and damage accrual. However, the natural history of Sjögren’s…Abstract Number: 2883 • 2018 ACR/ARHP Annual Meeting
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Background/Purpose: Autoantibodies are defining features of autoimmune diseases. How and why the autoantibodies are produced and how these autoantibodies relate to pathogenesis is poorly understood.…Abstract Number: 2884 • 2018 ACR/ARHP Annual Meeting
Correlation between Salivary Gland Ultrasonography, Minor Salivary Gland Histhopatology and Sialometry: Towards a Composite Assessment of Salivary Gland Involvement in Primary Sjögren’s Syndrome
Background/Purpose:: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease that specifically involves salivary glands. Several complementary tools including salivary gland ultrasonography (SGUS), histology and…Abstract Number: 2885 • 2018 ACR/ARHP Annual Meeting
Expansion of Activated PD-1+ ICOS+ T Follicular and Peripheral Helper Cells in Primary Sjögren’s Syndrome Associates with Abnormalities in B Cell Compartment
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by immune cell infiltration in the salivary glands resulting in ocular and oral dryness.…Abstract Number: 2886 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralizes IL-17A, provided significant and sustained improvement in the signs and symptoms of active PsA,…Abstract Number: 2887 • 2018 ACR/ARHP Annual Meeting
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
Background/Purpose: Pain remains a common and debilitating symptom in arthritis, despite good options to treat inflammation. In axial spondyloarthritis (axSpA), data on chronic pain remain…
ACR Meeting Abstracts